These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30133144)

  • 1. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L; Hou F; Liu Y; Li W; Zhang H
    J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D; Xu X; Wen J; Zhang C; Fan M
    Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H; Hara M; Iwakami SI; Takahashi K
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
    Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
    Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
    Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
    Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
    Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.
    Huang T; Engelmann BJ; Morgan RM; Absher KJ; Kolesar JM; Villano JL
    Cancer Chemother Pharmacol; 2018 May; 81(5):965-968. PubMed ID: 29610932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
    Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
    Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
    [No Abstract]   [Full Text] [Related]  

  • 18. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.